Also people have sometimes been quick to denigrate the value of Acromegaly- but actually the main competitor Acromegaly drug is worth $1 billy annually, and MS main competitor is $1.6 billy annually.
So I really don't think Acromegaly is anything to be shunned in terms of market potential. Anyone looking for more sexy should be doing a different web search I think.
Keeping in mind I suspect we have a better product in the pipeline (based on available data) for both MS and Acromegaly than anything else available in terms of dosage efficacy and cost- together, this is an outrageously strong market potential. Still have Asthma, bone marrow an cancer to go!
- Forums
- ASX - By Stock
- today
Also people have sometimes been quick to denigrate the value of...
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.0¢ |
Change
-0.002(2.44%) |
Mkt cap ! $82.94M |
Open | High | Low | Value | Volume |
8.3¢ | 8.3¢ | 7.9¢ | $287.6K | 3.558M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 939854 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.1¢ | 277962 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 939854 | 0.080 |
11 | 805876 | 0.079 |
6 | 506399 | 0.078 |
4 | 388042 | 0.077 |
5 | 296001 | 0.076 |
Price($) | Vol. | No. |
---|---|---|
0.081 | 277962 | 1 |
0.082 | 218868 | 1 |
0.083 | 37500 | 1 |
0.086 | 96543 | 1 |
0.089 | 200000 | 1 |
Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |